Remember "rember"? Data released in 2008 from Phase II trials involving 321 patients with mild and moderate Alzheimer’s disease revealed a 80% - 90% reduction in the rate of disease progression over two years in mild-moderate Alzheimer’s patients.

Well, the improved second generation rember is called LMTX and this is about to go into Phase 3 clinical trials!

Saw this exciting news:

Announcing a New Era in Alzheimer’s
The Time for Tau Is Now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer’s

· Event: Live Press Conference / Webinar in Conjunction with the 5th Clinical Trials Conference on Alzheimer’s Disease
· Speaker: Professor Claude Wischik, Co-founder and Chairman of TauRx Therapeutics Ltd
· Date: Tuesday, 30th October 2012
· Time: 16:00 – 16:45 Monte Carlo (Central European Time) / 15:00-15:45 London (GMT)
11:00-11:45 am NYC (EST) / 8:00-8:45 am Los Angeles (PST)

To register for the free Webinar by TauRx Chairman Prof Claude Wischik:
http://www.dontforgetalzheimers.com/

You can get video/audio on demand and the pdf slides if you miss the webinar.